Laures Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 11-12-2024
- Paid Up Capital ₹ 5.00 M
as on 11-12-2024
- Company Age 16 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.68 Cr
as on 11-12-2024
- Satisfied Charges ₹ 0.50 M
as on 11-12-2024
- Revenue %
(FY 2022)
- Net Worth 20.84%
(FY 2022)
- Total Assets 8.13%
(FY 2022)
About Laures Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹1.68 Cr. The company has closed loans amounting to ₹0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Alok Bansal and Ashwani Akolkar serve as directors at the Company.
- CIN/LLPIN
U24232RJ2008PTC027755
- Company No.
027755
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Nov 2008
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Laures Pharmaceuticals Private Limited offer?
Laures Pharmaceuticals Private Limited offers a wide range of products and services, including Pharmaceutical Medicine, Pharmaceutical Products, Metformin Tablets, Glimepiride Metformin Tablet, Vitamin Tablets & Capsules.
Who are the key members and board of directors at Laures Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Alok Bansal  | Director | 11-Jun-2012 | Current |
| Ashwani Akolkar | Director | 01-Aug-2013 | Current |
Financial Performance of Laures Pharmaceuticals.
Laures Pharmaceuticals Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth Soared by an impressive increase of 20.84%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Laures Pharmaceuticals?
In 2021, Laures Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Laures Pharmaceuticals (I) LlpActive 12 years 2 monthsAlok Bansal and Ashwani Akolkar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 16 Dec 2021 | ₹1.30 Cr | Open |
Hdfc Bank Limited Creation Date: 13 Nov 2020 | ₹1.27 M | Open |
Axis Bank Limited Creation Date: 15 Oct 2016 | ₹2.50 M | Open |
How Many Employees Work at Laures Pharmaceuticals?
Unlock and access historical data on people associated with Laures Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Laures Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Laures Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
